🇺🇸 FDA
Pipeline program

PREDNISOLONE , PREDNISONE , -, Ifinatamab Deruxtecan, PARACETAMOL , -, DOCETAXEL , -, -, -

MK-2400-001

Phase 3 small_molecule active

Quick answer

PREDNISOLONE , PREDNISONE , -, Ifinatamab Deruxtecan, PARACETAMOL , -, DOCETAXEL , -, -, - for Metastatic Castration-Resistant Prostate Cancer is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Metastatic Castration-Resistant Prostate Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials